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A Ab bs st tr ra ac ct t    The serious result of hepatitis B (HBV) virus infection is development of 
hepatocellular carcinoma (HCC). However, the reason of development of 
HCC in HBV infected patients is still unclear. Recently, the suppression of 
cell apoptosis is found to relate with the development of cell carcinogenesis, 
therefore, the expression of apoptosis inhibitor in the virus related cancer 
line such as hepatoma cell line HepG2.215 was investigated. There are at 
least six Human apoptosis inhibitors (IAP) have been identified now. They 
are cIAP1, cIAP2, XIAP, NAPI, survivin and pIAP. Using gene-assay 
t e c h n o l o g y ,  w e  h a v e  r e c e n t l y  c o m p a r e d  t h e  e x p r e s s i o n  o f  I A P s  i n  t h e  
HepG2.215 cells that persistently expresses Hepatitis B virus by integrated 
HBV genome with its parent cell line HepG2. The results suggest that there 
was obviously increase of cIAP2 and cIAP1 in the HepG2.215 cells versus 
HepG2 cells. Those observations imply a possibility of long time HBV 
infection could induce the over-expressing apoptosis inhibitors, furthermore, 
causing the liver cancer. The high expression of cIAP1 and cIAP2 in HBV 
expressing cells was confirmed by RT-PCR and Northern blot analysis. 
However, we did not find the change of NIAP and suvivin in HepG2.215 cells. 
In contrast, the expression of XIAP was down in the HepG2.215 cells 
comparing with HepG2 cells. How HBV triggers the over-expression of 
apoptosis inhibitor is unclear. Transient transfection of HepG2 cells with the 
plasmids expressing different HBV proteins such as S, M, L, X and core 
proteins did not give a decisive conclusion. Further study is going on now. 
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1.  Introduction 
Hepatitis B virus (HBV) is a major human pathogen responsible for acute and chronic liver disease. Worldwide, more than 350 
million people are chronically infected with HBV and more than one third of these individuals will develop into serious liver 
diseases such as primary hepatocellular carcinoma (HCC), if left untreated, which causes an estimated 1 million deaths annually [4]. 
Therefore, clarification of the relationship of HBV infection and the development of HCC, consequently developing the therapeutic 
method, is imperative. 
HBV is a small circular DNA virus, containing a nucleocapsid and an envelope. HBV nucleocapsid contains a relatively small 
incomplete double stranded DNA genome, viral polymerase and core protein. Its envelope is composed of viral surface proteins 
enclosed by a lipid membrane derived from host cells [11, 38], named LHBs, MHBs and SHBs, respectively to Large, middle and 
small surface protein [22]. Besides those viral proteins, HBV expresses a small non-structure protean named X protein, its function 
is still unclear. The role of HBV protein, particular of middle surface protein and X protein, in cell carcinogenesis is suggested [6, 
13, 14, 37, 17, 27], but is far away to the conclusion. Therefore, further investigation is needed.  
Recently, the studies have shown that the apoptotic cell death plays an important physiological role for normal cell 
development and tissue homeostasis. Dysregulation of apoptosis has been implicated in carcinogenesis, tumor progression and 
resistance of tumor cells to radio-and chemotherapy [28]. The molecular pathways leading to apoptosis are evolutionarily conserved 
and controlled by proteins that either promote or inhibit activation of a cascade of intracellular cysteine proteases known as caspases. 
Caspases can be divided into two groups based on the length of their prodomain and substrate specificity. The initiator caspase 
group includes caspase-2, caspase-8, caspase-9, and caspase-10, having long NH2-terminal prodomains, which interact with adapter 
molecules to form a death-inducing signaling complex. Downstream caspases such as caspase-3, caspase-6, and caspase-7 are 
executioner caspases that remain dormant until the initiator caspases activate them by proteolysis [8]. The activated executioner 
caspases cleave a number of structural and regulatory proteins, leading to apoptotic cell death [26].  
One kind of proteins that regulate cell apoptosis are named Apoptosis inhibitors (IAP), which include c-IAP1, c-IAP2, XIAP, 
NAIP, survivin, and currently discovered pIAP [8, 9, 15, 16, 20, 21, 25, 30, 31]. These proteins contain a novel 80 amino acid motif 
that is defined as the Baculovirus IAP repeat (BIR) [20], which probably prevents the proteolytic processing of procaspase-3, 
procaspase-6, and procaspase-7 by binding and blocking the activity of caspase-9. Increasing evidence demonstrated that IAPs are 
up regulated in many human tumor types and tumor cell lines [ 18, 32, 29, 39, 40] such as pancreatic carcinoma cells, lung cancer 
cells [7, 10 ], prostate cancer cells [24] and renal carcinoma cell line [28, 19, 44 ].  Other interesting finding is that the cancer cells 
resistant to the radio- and chemotherapy have obviously high level of IAP [3, 19, 36]. However, the reason why these IAPs are over-
expressed in tumor cell is unknown. 
Since HBV is a tumor trigger, we are interested in whether HBV could stimulate the over-expression of IAPs. Therefore, we 
have compared the IAPs expression in the persistently HBV expressing cell line HepG2.215 and its parent cell line, a non-HBV 
expressing cell line HepG2. We found that cIAP1 and cIAP2 were clearly increased in the HBV expressing cells but XIAP was 
down regulated. The other two IAPs, NIAP and suvivin, remain unchanged. The results suggest that the long time stimulation of 
HBV viral proteins indeed changes the expression of apoptosis profile of host cells, which probably results in the carcinogenesis of 
liver cells.    
2.  Materials and methods 
Cell lines and isolation of RNA  
HepG2 cell line was bought from ATCC and HepG2.215 cell line, which persistently produces Hepatitis B virus due to the 
integrated HBV genome, was kindly provided by Dr. Acs (Mt. Sinai Medical College, NY, NY). Both cell lines have been 
maintained in our laboratory for more than 8 years.  
Total RNA was isolated from 10
7 HepG2 cells or HepG2.215 cells using total RNA isolation Kit (Stratagene La Jolla, CA 
USA) as manufactory instruction. Briefly, cells were lysed with lysis buffer provided with Kit. Cell debris was removed by 
filtration. RNA was precipitated with ethanol and caught by RNA binding spin cup. After washing, DNA was degraded by the 
digestion of DNase. Finally RNA was released from cup and stored in –70° C for use.  
Micro-array analysis 
For gene array analysis, 100 µg RNA was reversely transcripted in to cDNA. cDNA fragments from mRNAs were 
fluorescently labeled and hybridized with chips contained more than 1,200  relative genes. Signal was detected and quantified. 
Mergen LTD (San Francisco, CA) performed the gene array analysis and result comparisons.  
Reverse-transcription PCR detection of IAPs  
One microgram RNA was used for the reverse-transcription PCR (RT-PCR). The reverse transcription was performed using 
RT-PCR kit (Stratagene, La Jolla, CA, USA), following by PCR amplification as described in our paper [22].  The primers with the 
sequence  3’-GAGGAGACAGTCCTACTGAAA (API1) and 3’-CATAGCATTATCCTTCGGTTC (API2)  were used to detect 
cIAP2. Primers with the sequence 3’-GGGAAGCAGAGATCATTTTGC (API3) and   3’- AACTGAGTATATCCATGTCCC 
(API4) were used to detect XIAP.  PCR bands were resolved in 1% agarose gel and quantified by software of AlphaIntertech. 
Northern Blot detection of IAPs RNA 
Ten micro grams RNA was resolved by 1% agarose gel electrophoresis. RNA was transferred to nylon membrane for Northern 
blot analysis.  “Northern” type blotting was performed essentially as described by Lu et al. [23]. The probe was made from PCR 
amplification of the plasmid containing IAPs sequence. Briefly, the plasmid containing IAPs DNA sequence was used as a template 
for PCR amplification. PCR was performed as described before except for 20µCi 32-P dCTP was used in place of the non-Int. J. Med. Sci. 2005 2(1) 
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radioactive dCTP [23]. 32-P labeled IAP fragments were purified by Probe Quant G50 micro column (Amersham, Piscataway, NJ). 
The membranes were hybridized with IAP probe (>10
7 cpm/ml) at 68° C, overnight. The images were acquired by phosphorimager. 
Detection of IAP proteins by immune-precipitation with anti-IAP antibody  
HepG2.2.15 cells or HepG2 cells were labeled by 35-S methionine (Amersham, Piscataway. NJ) as described in Lu et al. [23]. 
Briefly, 10
7 cells were washed with phosphate-buffered saline (PBS) three times, and incubated with 3 ml methionine minus RPMI 
1640 medium 30 minutes. Cells were labeled with 100µCi/ml 35-S methionine overnight. After washing with PBS, cells were 
released by trypsin digestion and then were lysed with 0.8ml Tris-HCl 0.05M pH 7.5, NaCl 0.15 M, MgCl2 0.005M, Np-40 0.2% at 
room temperature for 30 minutes. The nuclei and cell debris were removed by centrifugation at 14,000 rpm 5 minutes. The lysate 
was collected and the radioactivity was determined by Trichloroacetic acid (TCA) precipitation. For protein analysis, 100µl cell 
lysate was immune-precipitated with 30µl protein G beads (Roche, Switzerland) at 4° C overnight, which pre-absorbed with 
monoclonal anti-IAP antibody (1µg/ ml) (Zymed, Poli Alto, CA). After 4 washings with PBS, 0.05% Tween 20, the IAP proteins 
were released from beads through cooking at 95° C, 10 minutes in 20 µl sample buffer and resolved by 12.5 % sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred to polyvinyl difluoride (PVDF) membrane (Bio-
Rad, Hercules CA) and images were analyzed by Phosphorimager.  
3.  Results 
The profile of IAPs expression in the cells producing HBV  
The change of IAPs expression in the HBV expressing cells was first investigated by the comparison of the gene expression 
profile in the HepG2.215 and HepG2 cells using gene array technology.  
HepG2.215 is a cell line that derives from HepG2. The only difference between them is HepG2.215 cell is able to produce 
infectious viruses through the HBV genome integrated in the cell chromosome [1, 34, 35]. The results from gene array suggest that 
the expression of cIAP1 and cIAP2 genes was obviously higher in the HepG2.215 cells than in the HepG2 cells, approximately 1.6 
folds and 9 folds respectively (Table 1). The strong intensity of the dots implies that the increase of the expression of cIAP2 and 
cIAP1 most likely are reliable. In contrast, the gene expression of XIAP seemed to be 21 folds down in the HepG2.215 cells versus 
in the HepG2 cells (Table 1). However, the low expression of XIAP in the samples (negative intensity of the dot) probably lessens 
the significant of this difference. We will discuss this in detail late.  The expression of two other IAPs: NAIP and survivin, have not 
shown any changes by gene array (Table 1).    
Table 1. Analysis of IAPs expression in the HepG2.215 and HepG2 cells 
One hundred micrograms RNA from HepG2.215 and HepG2 cells 
were analyzed by gene array (Mergen LTD). The intensity of dots 
were calculated and standardized by computer. The comparison was 
then performed. 
 
Because the expressions of cIAP2 and XIAP in the cell 
line expressing HBV were dramatically altered, therefore, our next investigation focused in these two species.  
The up-regulation of cIAP2 in cells expressing HBV  
Figure 1. The over-
expression of cIAP2 in the 
HBV expressing cell line, 
HepG2.215. The RNA from 
HepG2.215 and HepG2 
cells were isolated. The 
expression of cIAP2 was 
examined with RT-PCR and 
Northern blot. A. RT-PCR 
detects cIAP2. One 
microgram RNA from 
HepG2 (number 1, 
duplicate) and HepG2.215 
cells (number 2, duplicate) 
were reverse- transcripted, 
and then amplified by PCR. 
The result from PCR was 
shown as a 434bp band. β-
Actin was used as a loading 
control. B. Northern blot 
detects cIAP2. Ten 
microgram RNA from 
HepG2 (number 1, duplicate) and HepG2.215 cells (number 2, duplicate) were separated by denature gel, then hybridized with 
cIAP2 specific probe. The cIAP2 and cIAP1 bands were indicated. β-Actin was used as a loading control as well. 
 
 
  HepG215/HepG2 (Fold)  Intensity of dots 
cIAP2 9.00  9.0357/-6.739 
cIAP1 1.60  67.037/35.824 
XIAP -21.9  -5.354/0.0414 
NIAP 1.00  -8.353/-11.45 
Survivin 1.00  -11.844/-8.3526 
cIAP2 
Actin
Mark 
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The increase of gene expression of cIAP2 in HepG2.215 cells was further investigated by the reverse transcription PCR (RT-
PCR) and Northern Blot. Using the specific primer set of IAP1/ IAP2 (See Materials and Methods), which amplifies the cAPI2 gene 
fragment from coding number 681 to 1014, a corresponding band with 434 base pairs was generated (Figure 1A). Figure 1A shows 
that the expression of cIAP2 was obviously higher in the HepG2.215, a cell line expressing HBV, than in the HepG2, a cell line 
absence of HBV (Figure 1A, 1&2). The up-regulation of cIAP2 expression in HepG2.215 cells is not due to an impact upon loading, 
at the same condition, the expression of β-Actin in both cell lines remained unchanged (Figure 1A). The up-regulation of cIAP2 
expression is consistent with the result from gene array analysis. 
The up-regulation of cIAP2 was confirmed by the Northern Blot analysis. After the hybridization with the probe specifying 
cIAP2, cIAP2 RNA appeared as a special band located in the place with the molecular weight around 8 kilo-base pair (Kb) (Figure 
1B). Because the cIAP2 and cIAP1 have 80% homogenous in their DNA sequence, the probe used to detect cIAP2 may detect the 
cIAP1 either [31, 43]. Therefore, the band with molecular weight around 4.5 kilo base pairs detected by cIAP2 probe was expected 
as the cIAP1 RNA (Figure 1B, the band below cIAP2 band). The nature of the third band below cIAP1 is unknown. However, it was 
also found in the testis cancer cells by Holcik et al. [15]. This band is studying in our laboratory now. 
Comparing with the HepG2 cells, the RNA level of cIAP2 in the HepG2.215 cells was obviously higher by the Northern Blot 
(Figure 1B, lane 2). This is agreement with the previous results from RT-PCR and gene array analysis. However, the increase of 
expression of cIAP1 was also can be observed in the HepG2.215 cells by Northern Blot (Figure 1B, lane 2), despite the cIAP1 
expressing level was not stronger as cIAP2.  The increase of the expression of cIAP2 and cIAP1 in the HepG2.215 cells were not 
due to the unequal loading of the samples, this is supported by the fact that the expression of the β-actin RNA in these samples was 
unchanged (Figure 1B). 
Detection of XIAP with RT-PCT and Northern Blot  
The change of another apoptosis inhibitor XIAP in the HBV expressing cell line was examined by RT-PCR and Northern blot 
too. The primer used to specify XIAP was IAP 3&4, which has generated a 575 base pairs band from RT-PCR (Figure 2A). The 
result suggests that the expression of XIAP in the HepG2.215 cells was a slightly down in the HBV expressing cell line, HepG2.215. 
This supports the conclusion from gene array. However, the noticeable down-regulation of XIAP in the HepG2.215 cell was not 
observed in the Northern blot (Figure 2B). Considering the expression of XIAP in the HepG2.215 cell was shown in the level of 
lower than background in the gene array (Table 1, intensity of XIAP), it is understandable that the slight decrease of XIAP in the 
HepG2.215 cells could be not 
detectable by Northern blot.  
Figure 2. The Detection of XIAP 
in the HepG2.215. The RNA 
from HepG2.215 and HepG2 
cells were isolated. The 
expression of XIAP was 
examined with RT-PCR and 
Northern blot as described in 
Figure 1. A. RT-PCR detects 
XIAP. B. Northern blot detects 
XIAP.  β-Actin was used as a 
loading control as well. 
 
 
The increase of cIAP2 protein in the HBV expressing cells  
In order to further investigate the up-regulation of cIAP2 at the translation level, the HepG2.215 cells and HepG2 cells were 
metabolically labeled with S
35 methionine. The cIAP2 then was immune-precipitated by 
anti-cIAP2 antibody (Zymed Laboratory, San Francisco, CA). Figure 3 shows that despite 
the loading of the control β-Actin has not shown difference, the cIAP2 protein with 6.8 kilo 
Dolton (KD) molecular weight in the HepG2.215 cells was obviously higher than that one 
in the HepG2 cells. This implies that the increase of cIAP2 in the HBV expressing cells was 
not only at the transcriptional level but also at the translational level.  
The cIAP2 usually forms a heterocomplex with TNF receptor 2 (TNFR2) and its 
associated factors: TRAF1 and TRAF2 [31]. Therefore, those proteins might be co-
precipitated with cIAP2 in our experiments. The band located beyond cIAP2 probably was 
the 73 KD big TNFR2. The two bands below the cIAP2 band were the 45 KD TRAF1 and 
56 KD TRFA2 respectively (Figure 3).  
Figure 3. The up-regulation of cIAP2 protein in HepG2.215 cells. HepG2.215 cells were 
labeled by 35-S Met. The cIAP2 was immune-precipitated by anti-cIAP2 antibody, and 
then resolved in SDS PAGE. The images were analyzed by Phosphorimager.  
 
4.  Discussion 
The increase of expression of apoptosis inhibitor is thought to be a major cause of the tumor formation/progression. Through 
the inhibition of cell apoptosis, cancer cells acquire the ability of unlimited growth. The molecular mechanisms by which the IAPs 
exert their antiapoptotic activity have been recently revealed. The main well-characterized mechanism is the inhibition of active 
XIAP
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caspases by the direct binding of IAPs. In the many case, for example, in the lung carcinoma cells, the interaction of the over-
expressed cIAP2 with caspase 9 prevents activating caspase3 that is an executer of apoptosis [10].  
One of the ways to stimulate IAPs expression is virus infection. Virus infection can change the host cell gene expression, 
furthermore, increasing the level of IAPs as we observed in our results. Some viral protein even itself is an apoptosis inhibitor [31]. 
In order to determine whether HBV could stimulate IAPs expression, the cell line HepG2.215 that persistently expresses HBV and 
its parent cell line HepG2 that does not express HBV were compared. Despite, opposed to normal human liver cell, the abnormal 
level of cIAPs expression in HepG2 was observed (our unpublished data), the expression of cIAPs in HepG2.215 cells, particularly 
of cIAP2, were much higher than that in HepG2 cells. Because the cIAPs are the important regulators of cell apoptosis, it is possible 
that HBV infection might alter the cIAPs gene expressing of liver cell, finally instigating the carcinogenesis of the cells it infected. 
This is agreement with the observation that the patients infected by HBV have high risk to develop to hepatocellular carcinoma 
(HCC). However, how HBV induces alteration of cIAPs expression, if it is true, what kind of HBV protein plays role in this 
alteration is unknown. In an attempt, we have expressed the different HBV proteins such as surface proteins (LHBs, MHBs and 
SHBs), core protein and HBV X protein (HBx) in the HepG2 cells respectively. Unfortunately, we did not find any change of the 
apoptosis inhibitors in these cells after the transfection (unpublished data). Considering the development of HCC in HBV infected 
patients is a long time process, perhaps, transient transfection would not obviously alter the expression of apoptosis inhibitor at all. 
Two viral peptides, the HBV X protein and the C-terminus of preS2 domain of surface protein, were found probably 
associating with the development of HCC [6, 13, 14, 37, 17]. However, the mechanism of how these proteins contribute to the 
carcinogenesis is still in the investigation. The involvement of these proteins in the NF-kB related signal transduction pathway that 
results in the cell apoptosis is one of the explanations.  
NF-kB, a family of transcription factors, is proven to be closely connected with the cell apoptosis. However, the different NF-
kB transcription factors may play diverse and even opposing roles in modulating cell death by apoptosis. The over-expression of 
NF-kB/RelA protects cells from tumor necrosis factor alpha (TNF-a)-or chemotherapy-mediated apoptosis [12, 32]. Enforced 
expression of NF-kB/RelA blocks apoptosis induced by a variety of proapoptotic agents, including TNF-a [39, 33]. In contrast, over-
expression of NF-kB/c-Rel in bone marrow cells triggers apoptosis. 
 The role of HBx in the activation of NF-kB transcription factors is very complex. HBx can activate NF-kB signal transduction 
pathway, but the reaction of the cell to HBx is dependent [37]. If HBx induces NF-kB/RelA, it results in the suppression of apoptotic 
cell death. In contrast, if HBx induces NF-kB/c-Rel, it promotes apoptotic cell death [37]. However, how HBx triggers different cell 
reactions is still unknown. Interestingly, the NF-kB has been shown to up-regulate the expression of cIAP2 and cIAP1 in multiple 
cell lines [5, 41, 45]. There is also evidence for cIAP2 induction by NF-kB is some systems [41, 42]. Therefore, it is possible that in 
the HBV infected cells, HBx probably activates the NF-kB/RelA, resulting in the up-regulation of IAPs, consequently, triggering the 
cell apoptosis. The up-regulation of IAP by NF-kB in the HBV infected cells needs further investigation. 
Using the transgenic mice, Hildt and his colleagues found that the PreS2 activators could exert a tumor-promoter-like function 
by activation of the PKC/c-Raf-1/MAP2-kinase signaling cascade that is a prerequisite for preS2-dependent activation of AP-1 and 
NF-kB [13, 14].  However, the activation of NF-kB transcription factors has been shown to correlate with the cell apoptosis, as we 
mentioned before, therefore, the preS2 activator perhaps also is responsible to the up-regulation of cIAPs in the HBV expressing 
cells.  
Altogether, the development of hepatocellular carcinoma perhaps is a result of long process of multi-genetic change of the 
HBV infection.  Nevertheless, the discovery of over-expression of cIAPs in the HBV expressing cells gives a possible way to study 
the relationship of cell apoptosis and the development of the carcinogenesis. 
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